Post Views: 221

BioRestorative Therapies Inc (OTCMKTS: BRTXQ) is heating up fast in recent trading and heading northbound again after several weeks of choppy waters. BioRestorative is among the most exciting stories in small caps that has attracted legions of new shareholders after the Company partnered on a new bankruptcy reorganization plan with one of its creditors Auctus Capital in which it would emerge from bankruptcy with the commons intact, ready to begin phase 2 trials and get BioRestorative back on a national stock exchange.

Penny stock speculators are accumulating BRTXQ as they wait for Judge Grossman to say the word EFFECTIVE. There is a lot of speculation on exactly when this will hapen considering the Judges schedule with holidays, COVID-19, and a logjam of cases on the docket. Interested shareholders are monitoring the developments on PACER.

BioRestorative Therapies Inc (OTCMKTS: BRTXQ) operating out of Melville, New York is a life sciences company focused on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. We develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs are: Disc/Spine Program (brtxDISCTM): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous cultured mesenchymal stem cells collected from bone marrow. The Company intends that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The Company has received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. Metabolic Program (ThermoStem): BioRestorative is developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

BioRestorative Therapies is developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells, or BADSC, to generate brown adipose tissue, or BAT. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning, as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

To Find out the inside Scoop on BioRestorative Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BioRestorative owns a valuable intelectual property portfolio including unique international Stem Cell patents as well as 8 patents issued, in the United States and other countries, for the Companys brown fat technology related to BioRestoratives metabolic program (ThermoStem Program).

On March 20 BioRestorative filed a voluntary petition commencing a case under chapter 11 of title 11 of the U.S. Code in the United States Bankruptcy Court for the Eastern District of New York. The Companys chapter 11 case is being administered under the caption, In re: BioRestorative Therapies, Inc., Case No. 8-20-71757.

Initially intellectual property lawyer John Desmarais entered into a stalking horse agreement to buy the company. He would pay $500,000 to acquire the company, along with their assets (including the intellectual property). The deal with Desmarais fell apart in July when Auctus Capital partnered with the Company on a new bankruptcy reorganization plan in which the Company would emerge from bankruptcy with the commons intact, ready to begin their phase 2 trials and get BioRestorative back on a national stock exchange. On September 10th, a hearing was held for confirmation of the bankruptcy reorganization plan submitted jointly by the company and Auctus Capital Partners. Further detail will be added upon review of the judges order, but the plan and disclosure statement are available to Pacer or Pacermonitor subscribers.

We have a Monster Pick Coming. Subscribe Right Now!

Currently on the move and running northbound again after several weeks of choppy waters BRTXQ is an exciting story developing in small caps; BioRestorative filed for bankruptcy protection in March but has partnered on a new bankruptcy reorganization plan with one of its creditors Auctus Capital in which the Company would emerge from bankruptcy with the commons intact, ready to begin their phase 2 trials and get BioRestorative back on a national stock exchange. Penny stock speculators are accumulating BRTXQ as they wait for Judge Grossman to say the word EFFECTIVE. There is a lot of speculation on exactly when this will happen considering the Judges schedule with holidays, COVID-19, and a logjam of cases on the docket. Interested shareholders are monitoring the developments on PACER.We will be updating on BioRestorative when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with BioRestorative.

Disclosure: we hold no position in BRTXQ either long or short and we have not been compensated for this article.

Share.

View original post here:
Q Stock; The Rise of BioRestorative Therapies Inc (OTCMKTS: BRTXQ) - MicroCap Daily